Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a private-label version up to 75% off the cash price of brand-name analog insulins in a bid to “improve access and lower the cost of care.” But the move was met with a mix of derision and skepticism.
The retailer announced it will sell rapid-acting analog insulin, which is a genetically modified form of human insulin, at $72.88 for a vial and $85.88 for a box of injectable pens. By doing so, the company maintained that anyone who pays cash will be able to save up to $101 off a brand-name vial or $251 off a package of five pens.
“The price of treatment compared to what is available today is real innovation,” Cheryl Pegus, executive vice president of health & wellness at Walmart, said in a call with reporters. “Our goal is to allow people to treat their health faster.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
